Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.53 |
| ▸ | APP | P05067 | 6/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079237 | 0.93 | AKR1C1 (0.65) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL30487797 | 0.93 | AKR1C1 (0.65) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL2535205 | 0.93 | AKR1C1 (0.59) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL435932 | 0.91 | AKR1C1 (0.62) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL3219884 | 0.91 | AKR1C1 (0.62) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL5768673 | 0.89 | AKR1C1 (0.46) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL6505689 | 0.89 | CYP2D6 (0.48) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL1626768 | 0.89 | ALDH1A1 (0.48) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL13887009 | 0.84 | AKR1C1 (0.41) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL4320025 | 0.84 | KCNN4 (0.47) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-14 | — | — | US | claimed |
| WO-2007147574-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| EP-1870416-A1 | Sulphonamido-macrocycles as tie2 inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | claimed |
| WO-2025128626-A1 | HYBRID PEPTIDE COMPOUNDS HAVING A MODIFIED LYSINE RESIDUE | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025128624-A2 | HYBRID PEPTIDE COMPOUNDS HAVING A SUBSTITUTED TRYPTOPHAN RESIDUE OR A TERMINAL SUBSTITUENT | CARMOT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-113861072-A | Preparation method of aryl cyclopropane compound | 上海麦克林生化科技有限公司 | 2021-12-31 | — | — | CN | disclosed |
| US-20200299292-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-A]PYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | EPIGENETIX, INC. | 2020-09-24 | — | — | US | disclosed |
| CN-109589325-B | A kind of pharmaceutical composition and preparation method thereof for treating enteritis | 牡丹江医学院 | 2019-11-26 | — | — | CN | disclosed |
| CN-109589325-A | A kind of pharmaceutical composition and preparation method thereof for treating enteritis | 牡丹江医学院 | 2019-04-09 | — | — | CN | disclosed |
| US-20190031657-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-A]PYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | EPIGENETIX, INC. | 2019-01-31 | — | — | US | disclosed |
| CN-109219602-A | Modulators of cystic fibrosis transmembrane conductance regulator proteins | 艾伯维公司 | 2019-01-15 | — | — | CN | disclosed |
| WO-2011061277-A1 | AMINO ARYL ACETAMIDES AND THEIR USE IN THE TREATMENT OF MALARIA | GLAXO GROUP LIMITED (GB) | 2011-05-26 | — | — | WO | disclosed |
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-14 | — | — | US | disclosed |
| EP-1870416-A1 | Sulphonamido-macrocycles as tie2 inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2004043911-A2 | N-CYCLOALKYLGLYCINES AS HIV PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | TIE1, KDR, TEK | AKR1C1 962/4885APP 2347/4885CYP2C19 1997/4885 |
| US-20200299292-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-A]PYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BRD4, BRD3, BRPF3 | AKR1C1 2924/4885APP 3673/4885CYP2C19 2617/4885 |
| US-20190031657-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-A]PYRIDINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BRD4, BRD3, BRPF3 | AKR1C1 2924/4885APP 3673/4885CYP2C19 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.